{
  "abstract": "Liver fibrosis remains the critical bottleneck in the progression from chronic liver injury to cirrhosis and hepatocellular carcinoma (HCC). Activated hepatic stellate cells (HSCs) play a central role in this process by secreting excessive extracellular matrix leading to liver scarring, distortion of liver architecture and liver dysfunction.1 Despite intensive efforts to target HSCs and reverse fibrosis, no treatment has yet reached the clinic.",
  "authors": [
    {
      "affiliations": [
        "Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain",
        "Instituto de Investigaciones Sanitarias de Navarra IdiSNA, Pamplona, Spain",
        "CIBERehd, Instituto de Salud Carlos III, Madrid, Spain"
      ],
      "name": "Maria Arechederra"
    },
    {
      "affiliations": [
        "Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, Netherlands",
        "Translational Liver Research, Personalized Diagnostics and Therapeutics, University of Twente, Enschede, Netherlands",
        "Department for General, Visceral and Transplant Surgery, University Hospital Münster, Münster, Germany"
      ],
      "name": "Ruchi Bansal"
    }
  ],
  "title": "ISG15–CREB1 ISGylation: a stellate cell brake in liver fibrosis",
  "uid": "6b16ab44-e5c8-5cf6-a640-381f7f1aa9e5"
}